Negotiators Prioritize Generic And Biosimilar Oncology Drugs Over Newer Medicines

UICC And WHO Will Bargain For Cheaper Cancer Drugs For LMICs

The Union for International Cancer Control and the World Health Organization are prioritizing off-patent drugs in their efforts to facilitate oncology medicine access in developing nations.

Pills and syringes lying on top of a sheet of paper reading 'Cancer treatment'
Lack of screening and treatment in LMICs is leading to high cancer mortality • Source: Shutterstock

The Union for International Cancer Control and the World Health Organization have both chosen to prioritize generic and biosimilar cancer drugs in their efforts to improve access to treatment across low- to middle-income countries, rather than focusing on new technologies like immunotherapy.

Speaking at the World Cancer Congress 2022 last month, UICC CEO Gary Adams explained that the organization is engaging with generic and biosimilar medicine producers to find ways of increasing supply of their medicines to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

More from Policy & Regulation